Genfit S.A. (OTCMKTS:GNFTF – Get Free Report) shares fell 40.2% on Friday . The company traded as low as $3.32 and last traded at $3.32. 100 shares traded hands during trading, a decline of 83% from the average session volume of 588 shares. The stock had previously closed at $5.55.
Genfit Stock Performance
The company’s 50 day moving average price is $5.51 and its 200-day moving average price is $5.15.
About Genfit
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Featured Articles
- Five stocks we like better than Genfit
- How to Use Stock Screeners to Find Stocks
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- What Do S&P 500 Stocks Tell Investors About the Market?
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- Best Aerospace Stocks Investing
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
